RougeTx launches with $58M Series A led by BioGeneration Ventures, Angelini Ventures, and Kurma Partners to advance first-in-class HHT treatment.
Amount Raised
$58 Million
Round Type
Series A
North HollandBiotechnologyHealth CareTherapeuticsInvestors
Description
RougeTx, a preclinical-stage biotechnology company, announced its launch with a $58 million Series A financing round. The round was co-led by BioGeneration Ventures, Angelini Ventures, and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, and Kerna Ventures. The funding will support RTX-001, the company's lead program, as it advances toward first-in-human clinical development for hereditary hemorrhagic telangiectasia (HHT). RougeTx is developing first-in-class disease-modifying therapies designed to restore vascular integrity by targeting pericyte dysfunction.
Fundz sees it the moment RougeTx raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansRougeTx raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.